Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy.
AZA
CAR T cells
gene expression
leukemia
patient-derived xenografts
Journal
ImmunoTargets and therapy
ISSN: 2253-1556
Titre abrégé: Immunotargets Ther
Pays: New Zealand
ID NLM: 101606565
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
01
2021
accepted:
24
02
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
7
5
2021
Statut:
epublish
Résumé
Despite the success of chimeric antigen receptor (CAR) T cells in clinical studies, a significant proportion of responding patients eventually relapsed, with the latter correlating with low CAR T cell expansion and persistence. Using patient-derived xenograft (PDX) mouse models of CD19 We propose that treatment with AZA activates OX40L/OX40 co-stimulatory signaling in CAR T cells. Our data suggest that the clinical use of AZA before CAR T cells could be considered.
Identifiants
pubmed: 33954150
doi: 10.2147/ITT.S296161
pii: 296161
pmc: PMC8091475
doi:
Types de publication
Journal Article
Langues
eng
Pagination
123-140Informations de copyright
© 2021 Xu et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Exp Hematol. 2013 Jan;41(1):39-55.e10
pubmed: 22999867
Biotechnol J. 2018 Feb;13(2):
pubmed: 28840981
PLoS One. 2012;7(8):e41277
pubmed: 22870213
J Immunol. 1999 May 15;162(10):5671-5
pubmed: 10229797
Nature. 2015 Nov 12;527(7577):249-53
pubmed: 26503055
Cancer Discov. 2011 Dec;1(7):598-607
pubmed: 22586682
Onco Targets Ther. 2019 Jul 12;12:5627-5638
pubmed: 31372000
Crit Rev Immunol. 2009;29(3):187-201
pubmed: 19538134
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
Cell Physiol Biochem. 2018;48(1):111-119
pubmed: 30001552
Cancer Res. 2016 Apr 1;76(7):1683-9
pubmed: 26988985
Annu Rev Immunol. 2010;28:57-78
pubmed: 20307208
Oncoimmunology. 2012 Jul 1;1(4):458-466
pubmed: 22754764
Semin Oncol. 2015 Jun;42(3):506-13
pubmed: 25965370
J Immunother Cancer. 2013 Sep 23;1:17
pubmed: 24829753
Epigenetics. 2014 Mar;9(3):459-67
pubmed: 24394348
Sci Transl Med. 2017 Nov 22;9(417):
pubmed: 29167392
Clin Cancer Res. 2013 Apr 1;19(7):1795-805
pubmed: 23426279
Cancer Discov. 2019 Mar;9(3):370-383
pubmed: 30409776
Oncoimmunology. 2015 Apr 2;4(8):e1019978
pubmed: 26405573
Sci Signal. 2018 Aug 21;11(544):
pubmed: 30131370
Front Oncol. 2020 May 06;10:697
pubmed: 32435621
Cancer Immunol Res. 2015 Sep;3(9):1030-41
pubmed: 26056145
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385
pubmed: 30837712
Blood Cancer J. 2014 Mar 28;4:e197
pubmed: 24681961
Exp Hematol. 2015 Dec;43(12):1001-1014.e5
pubmed: 26384559
J Clin Invest. 2011 May;121(5):1822-6
pubmed: 21540550
Cancer Cell. 2015 Oct 12;28(4):415-428
pubmed: 26461090
Mol Ther. 2018 Aug 1;26(8):1883-1895
pubmed: 29861327
Cancer Immunol Immunother. 2016 Jul;65(7):787-96
pubmed: 26646852
Eur J Immunol. 2006 May;36(5):1093-103
pubmed: 16541471
Comput Struct Biotechnol J. 2018 Nov 22;17:1-13
pubmed: 30581539
Cancer Discov. 2013 Apr;3(4):388-98
pubmed: 23550147
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Int J Mol Sci. 2019 Mar 14;20(6):
pubmed: 30875739
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Immunity. 2001 Sep;15(3):445-55
pubmed: 11567634
Immunotherapy. 2017 Jan;9(2):123-130
pubmed: 28128714
Clin Epigenetics. 2017 May 30;9:59
pubmed: 28572863
Haematologica. 2021 Apr 01;106(4):987-999
pubmed: 32381575
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
Blood Adv. 2018 Feb 13;2(3):210-223
pubmed: 29386194